AperçuGraphiqueProfilStatistiques clésDonnées financièresTechniqueActualitésTraderScreen

DKSH N/  CH0126673539  /

SIX Swiss Exchange
08/11/2024  17:31:57 Chg. +0.80 Volume Bid17:40:00 Demandez à17:40:00 Capitalisation boursière Dividende Y. Rapport P/E
66.50CHF +1.22% 74,116
Chiffrre d'affaires: 4.9 Mio.		 63.80Bid taille: 65 67.70Ask la taille: 198 4.33 Mrd.CHF 3.38% 23.75
GlobeNewswire 26/08 Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
GlobeNewswire 15/08 Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire 15/08 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...
GlobeNewswire 01/08 Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Confere...
GlobeNewswire 22/07 STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Euro...
GlobeNewswire 11/07 Alvotech Announces Closing of Private Debt Financing
GlobeNewswire 02/07 Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire 01/07 Alvotech Issues New Shares to Holders of Convertible Bonds
GlobeNewswire 01/07 Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
GlobeNewswire 26/06 Alvotech Receives Conversion Notices for Majority of Convertible Bonds
GlobeNewswire 18/06 Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD ...
GlobeNewswire 11/06 Alvotech and STADA add to strategic alliance through denosumab partnership
GlobeNewswire 07/06 Alvotech Announces Strategic Refinancing Agreement
GlobeNewswire 29/05 Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
GlobeNewswire 21/05 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire 21/05 Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire 21/05 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire 13/05 Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (...
GlobeNewswire 02/05 Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
GlobeNewswire 30/04 U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire 24/04 Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimil...
GlobeNewswire 19/04 Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...
GlobeNewswire 16/04 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
GlobeNewswire 03/04 Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
GlobeNewswire 22/03 Alvotech Announces Increase in Number of Own Shares